In turn, present results suggest that the treatment of patients with OU or possibly other CGs could be pursued only after the molecular characterization of breast tumors has evidenced a high expression of ATP1A3 and a low expression of ATP1A1 and ATP1B1. This evidence concerns the gene ATP1A3 and breast neoplasm.